Study guide

9.2 Controlled Substance Safety & Opioid Stewardship

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

9.2 Controlled Substance Safety & Opioid Stewardship

Key Takeaways Explain This Topic AI

Universal precautions mean applying the same risk assessment, monitoring, and documentation to every patient prescribed opioids rather than profiling based on appearance or demographics.

Tolerance and physical dependence are expected physiologic adaptations to chronic opioid therapy and are not addiction; addiction is defined by compulsive use and continued use despite harm.

Naloxone should be co-prescribed when the daily morphine milligram equivalent is high, when opioids are combined with benzodiazepines, and when there is a history of overdose or substance use disorder.

A urine drug test that is negative for the prescribed opioid can indicate diversion, non-adherence, or an assay that does not detect that specific drug, so confirmatory testing and a conversation must precede any accusation.

Federal law prohibits refills on Schedule II prescriptions, but a prescriber may issue multiple sequential prescriptions on the same day authorizing up to a 90-day supply provided each specifies the earliest fill date.

Last updated: August 2026

9.2 Controlled Substance Safety & Opioid Stewardship

Blueprint focus: ONCC Domain II.O — Controlled substance safety. This blueprint item is separate from pain management itself. It asks whether the nurse practitioner can prescribe opioids safely and legally while still treating cancer pain adequately.

The Central Tension

Undertreated cancer pain is a documented harm, and so is opioid-related overdose. The regulatory environment built after the opioid crisis was largely designed around chronic non-cancer pain, and applying it uncritically to a patient with bone metastases causes real suffering. The answer is neither reflexive prescribing nor reflexive restriction; it is stewardship — the right drug, the right dose, the right monitoring, and documentation that would withstand review.

The 2022 CDC clinical practice guideline explicitly states that its dose thresholds are not intended as inflexible limits and that patients with cancer-related pain, sickle cell disease, and palliative or end-of-life care warrant individualized management. Quoting an arbitrary milligram ceiling at a patient with progressive malignancy is a misapplication of that guidance.

Universal Precautions

Apply the same structured approach to every patient started on an opioid. This is both safer and more equitable, since clinician "gut feeling" about who might misuse medication tracks race and socioeconomic status far more than it tracks actual risk.

Establish and document the pain diagnosis and the mechanism.

Assess risk with a validated tool before the first prescription.

Check the prescription drug monitoring program (PDMP) database.

Obtain a baseline urine drug test .

Set explicit treatment goals — a function target, not only a numeric pain score.

Use a treatment agreement describing one prescriber, one pharmacy, refill procedure, storage, and the conditions under which the plan changes.

Re-evaluate at defined intervals using the four A's : Analgesia, Activities of daily living, Adverse effects, and Aberrant behaviors.

Document the reasoning, not just the prescription.

Risk stratification tools

Opioid Risk Tool (ORT) — brief; scores personal and family history of substance use, age, history of preadolescent sexual abuse, and psychological disease.

SOAPP-R (Screener and Opioid Assessment for Patients with Pain, Revised) — 24 items, predicts aberrant medication-related behavior.

COMM (Current Opioid Misuse Measure) — designed for ongoing monitoring rather than initial screening.

A high score does not withhold analgesia. It changes structure : shorter prescription intervals, more frequent visits, pill counts, more frequent urine testing, single-pharmacy dispensing, and addiction medicine co-management.

Terminology the Exam Tests

Term Definition Implication

Tolerance Reduced effect from the same dose over time Expected physiologic adaptation; requires dose adjustment, not concern about addiction

Physical dependence Withdrawal syndrome on abrupt cessation or antagonist administration Expected; requires tapering rather than abrupt discontinuation

Addiction (opioid use disorder) Compulsive use, loss of control, craving, continued use despite harm A treatable disease requiring addiction medicine involvement, not abandonment

Pseudoaddiction Drug-seeking behavior driven by undertreated pain that resolves once analgesia is adequate Reassess whether the dose is sufficient before labeling behavior as misuse

Diversion Transfer of a prescribed drug to someone else A criminal and safety issue distinct from addiction

Confusing tolerance or physical dependence with addiction is the single commonest conceptual error in opioid prescribing, and it drives inappropriate under-dosing of patients with advanced cancer.

Monitoring Tools in Practice

PDMP. Query before initiating and at defined intervals, per state law. Look for multiple prescribers, multiple pharmacies, overlapping benzodiazepine prescriptions, and early fills. A concerning pattern opens a conversation; it does not by itself justify abrupt discontinuation.

Urine drug testing. Two important interpretive points:

A negative result for the prescribed opioid may mean diversion, non-adherence, or an assay limitation. Standard immunoassay opiate screens detect morphine and codeine but frequently miss oxycodone, methadone, fentanyl, and buprenorphine , all of which require specific assays or confirmatory mass spectrometry.

Unexpected positives must be interpreted against metabolic pathways: codeine metabolizes to morphine, hydrocodone to hydromorphone, and heroin to 6-monoacetylmorphine and then morphine. A morphine-positive result in a patient prescribed codeine is expected, not evidence of misuse.

Discuss discrepancies with the patient before drawing conclusions, and send confirmatory testing.

Naloxone co-prescribing. Offer take-home naloxone and train the patient and household when any of the following apply: a high daily morphine milligram equivalent, concurrent benzodiazepine or other sedative, history of overdose or substance use disorder, sleep-disordered breathing, significant renal or hepatic impairment, or an older adult living alone.

Storage and disposal. Teach patients to store opioids in a locked box, never in an unsecured medicine cabinet or purse, and never to share. For disposal, direct patients to DEA take-back sites or pharmacy kiosks. Fentanyl patches are the notable exception to disposal caution: because a used patch retains enough drug to kill a child or pet, patients are instructed to fold the adhesive sides together and dispose of it as directed by the label, which for fentanyl explicitly permits flushing.

Federal Prescribing Rules

Schedule II substances (morphine, oxycodone, hydromorphone, fentanyl, methadone, methylphenidate): no refills are permitted. Each dispensing requires a separate prescription. A prescriber may, however, issue multiple prescriptions on the same day authorizing up to a 90-day total supply , provided each prescription bears the earliest date on which it may be filled and this is permitted by state law.

Schedules III and IV : up to five refills within 6 months of the issue date.

Electronic prescribing of controlled substances is required for Medicare Part D and increasingly by state law.

The DATA-2000 waiver ("X waiver") was eliminated by the Consolidated Appropriations Act of 2023, so any clinician with a standard DEA registration may now prescribe buprenorphine for opioid use disorder — relevant when a cancer patient also needs treatment for a substance use disorder.

State law may be more restrictive than federal law on quantity limits, mandatory PDMP checks, and days-supply caps for opioid-naive patients.

Cancer Pain in Patients With Substance Use Disorder

These patients have cancer pain and deserve treatment for it.

Do not withhold opioids because of a substance use history. Untreated pain drives relapse.

Involve addiction medicine and palliative care early and co-manage.

Use structure : short prescription intervals, weekly or biweekly dispensing, pill counts, single pharmacy, more frequent urine testing.

Prefer long-acting scheduled dosing over large as-needed quantities, which reduces the reinforcing peak-and-trough pattern.

Patients on buprenorphine or methadone maintenance can and should continue it. Buprenorphine is generally continued through cancer treatment, with additional full-agonist opioid titrated for acute pain; abruptly stopping maintenance therapy destabilizes both the pain and the addiction.

Maximize non-opioid and interventional options: adjuvants, radiation to painful bone metastases, nerve blocks, and intrathecal pumps.

Document objectively and without pejorative language. "Requested an early refill and reported that the dose lasts 5 hours" is useful; "drug-seeking" is not.

Loading diagram... Universal Precautions in Opioid Prescribing for Cancer Pain